StockData
Nexalin Technology, Inc. logo

Nexalin Technology, Inc. (NXL) shareholders

NXLNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$1.44−0.06 (-4.00%)

Close on Nov 18, 2026Market cap $31.73MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
0.1%
0M of 22M shares
Institutional holders
20
4 new, 7 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Alumni Capital LP
Joint filing with Alumni Capital GP LLC (9.99%), Ashkan Mapar (9.99%)
2,493,0759.99%13G (passive)Aug 19, 2026
Greenlight Ventures, LLC1,385,2465.60%13D (active)Aug 18, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of NXLValueChange% of portfolio
Peak6 LLC8,0070.04%$79.27K−4,8080.00%
Geode Capital Management, LLC4,6530.02%$46.06K−3,5810.00%
Vanguard Capital Management LLC4,2180.02%$41.76K–0.00%
Citadel Advisors LLC2,5130.01%$24.88KNew0.00%
Jane Street Group, LLC2,1840.01%$21.61K+1,8340.00%
Vanguard Fiduciary Trust Co1,7130.01%$16.96K–0.00%
State Street Corp1,0770.00%$10.66K–0.00%
UBS Group AG8940.00%$8.85K+1550.00%
Northern Trust Corp8030.00%$7.95K–0.00%
Kovack Advisors, Inc.7440.00%$8.04K−340.00%
StoneX Group Inc.4500.00%$5.41K−3140.00%
Raymond James Financial Inc4030.00%$3.99K–0.00%
Integrated Investment Consultants, LLC3330.00%$3.30K–0.00%
Osaic Holdings, Inc.700.00%$693–0.00%
Tower Research Capital LLC (TRC)700.00%$697–0.00%
Citigroup Inc490.00%$481New0.00%
Wells Fargo & Company/Mn330.00%$330–0.00%
Farther Finance Advisors, LLC330.00%$330–0.00%
Federation des caisses Desjardins du Quebec290.00%$288New0.00%
Barclays PLC80.00%$80New0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026200M0.1%4 / 24 / 70M0M
Q1 2026230M0.2%9 / 37 / 40M0M
Q4 2025190M0.3%5 / 91 / 60M0M
Q3 2025200M0.1%4 / 46 / 40M0M
Q2 2025210M0.2%9 / 40 / 50M0M
Q1 2025170M0.1%3 / 34 / 50M0M
Q4 2024190M0.1%11 / 61 / 70M0M
Q3 2024150M0.1%8 / 13 / 50M0M
Q2 2024130M0.0%10 / 21 / 20M0M
Q1 202450M0.0%2 / 10 / 00M0M
Q4 202330M0.0%0 / 00 / 20M0M
Q3 202350M0.0%3 / 00 / 20M0M

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Mark WhiteCEO, Director309,1271.40%Dec 23, 2025
David OwensChief Medical Officer, Director191,2520.87%Dec 23, 2025
Carolyn Hamby SheltonSr. VP - Quality - Regulatory54,0000.25%Dec 23, 2025
Fleet Justin VanCFO25,0000.11%Dec 23, 2025
Alan KazdenDirector119,5900.54%Dec 23, 2025
Ben HuDirector381,2611.73%Dec 23, 2025
Greenlight Ventures, LLC10% owner133,4750.61%Nov 17, 2026
Marilyn Elson–1,535,2446.97%Sep 30, 2025
Leonard Osser10% owner2,453,82111.14%Sep 30, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Alan Kazden
Director
Sep 29, 2025Award+36,459––119,590
David Owens
Chief Medical Officer, Director
Sep 29, 2025Award+36,459––191,252
Leonard Osser
10% owner
Sep 29, 2025Award+83,333––1,618,577
Ben Hu
Director
Sep 29, 2025Award+36,459––377,095
Carolyn Hamby Shelton
Sr. VP - Quality, Regulatory
Mar 12, 2025Buy+6,000$2.20$13.20K30,000
David Owens
Chief Medical Officer, Director
Feb 4, 2025Buy+1,000$3.10$3.10K155,793
David Owens
Chief Medical Officer, Director
Feb 4, 2025Buy+1,000$2.98$2.98K154,793
David Owens
Chief Medical Officer, Director
Jan 28, 2025Buy+1,500$2.70$4.05K153,793
David Owens
Chief Medical Officer, Director
Jan 23, 2025Buy+1,000$2.70$2.70K152,293
David Owens
Chief Medical Officer, Director
Jan 13, 2025Buy+2,000$2.50$5.00K151,293
David Owens
Chief Medical Officer, Director
Dec 20, 2024Buy+1,000$2.75$2.75K149,293
David Owens
Chief Medical Officer, Director
Oct 28, 2024Buy+500$2.19$1.10K148,293
Carolyn Hamby Shelton
Senior VP
Oct 14, 2024Buy+24,000$0.85$20.40K24,000
Ben Hu
Director
Sep 30, 2024Award+175,000––340,636
Marilyn Elson
10% owner
Sep 30, 2024Award+700,000––1,535,244
Leslie Bernhard
Director
Sep 30, 2024Award+49,838––49,838
Leonard Osser
–
Sep 23, 2024Award+700,000––1,535,244
David Owens
Chief Medical Officer, Director
Aug 13, 2024Buy+1,000$0.95$950147,793
David Owens
Chief Medical Officer, Director
Jun 28, 2024Buy+1,000$1.75$1.75K146,793
David Owens
Chief Medical Officer, Director
Jun 18, 2024Buy+1,619$0.71$1.15K145,793
David Owens
Chief Medical Officer, Director
Jun 10, 2024Buy+1,000$0.62$620144,174
David Owens
Chief Medical Officer, Director
Jun 10, 2024Buy+2,000$0.65$1.30K143,174
Leonard Osser
–
Sep 28, 2022Buy+9,500$1.12$10.64K835,244
Alan Kazden
Director
Sep 16, 2022Buy+2,500$4.15$10.38K83,131
Rick Morad
Director
Sep 16, 2022Buy+2,500$4.15$10.38K108,341
Alan Kazden
Director
Sep 16, 2022Buy+2,500$4.15$10.38K89,131
Rick Morad
Director
Sep 16, 2022Buy+2,500$4.15$10.38K107,989
Leonard Osser
–
Sep 16, 2022Buy+36,000$4.15$149.40K825,744
David Owens
Chief Medical Officer, Director
Sep 16, 2022Buy+2,500$4.15$10.38K141,174
Mark White
President/CEO, Director
Sep 16, 2022Buy+2,500$4.15$10.38K289,627
Mark White
President/CEO, Director
Sep 15, 2022Buy+25,000$4.15$103.75K309,127
Mark White
President/CEO, Director
Sep 15, 2022Buy+25,000$4.15$103.75K289,627

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
0.07%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
+180.7%
From 0M shares
Short volume, 20 days
36.7%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Nexalin Technology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 377,263 shares on Oct 2, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Marilyn Elson
Associate to Affiliate
Sep 10, 202523,150$403Sep 10, 2025Open Market Purchase

See a number that looks wrong?